TELANGANA WAGES WAR AGAINST COUNTERFEIT DRUGS
Bio Spectrum|BioSpectrum India Oct 2024
Telangana contributes nearly one-third to India’s production and one-fifth to its exports in the pharmaceutical sector.
Amguth Raju
TELANGANA WAGES WAR AGAINST COUNTERFEIT DRUGS

Hyderabad is a home to 800 pharma companies and life sciences capital of the country. To make the state free of spurious drugs, the Drugs Control Administration (DCA), Telangana is working relentlessly to detect spurious drugs movement in the market. In 2023 the DCA has carried out 26,133 inspections and taken action in 4984 cases with 4991 cases of violations. In the first four months of this year till April 2024 DCA has carried out 8495 inspections and found out that 50 drugs are ‘Not of Standard Quality’ (NSQ). Let’s look at how DCA is continuing its crusade against the spurious drugs issue and keep the public health of the state in order.

From the beginning of 2024, the DCA of Telangana, under the leadership of Director General (DG) V B Kamalasan Reddy, (who took charge as DG in July 2023) has intensified its efforts to combat the menace of spurious, fake and NSQ in the state. In the past few months, the DCA has targeted nearly 100 facilities across the state, resulting in the confiscation of 4000 to 5000 kgs of counterfeit medications worth Rs 50-60 crore. These recent raids have uncovered a widespread network of spurious drugs, highlighting the ongoing battle against counterfeit medications that pose a severe threat to public health.

Highlighting the efforts taken by the DCA of Telangana, Kamalasan Reddy said that he is committed to ensuring that quality, efficacy, and safety of medicines being supplied to the people in the state. “As part of this objective, we at the DCA have set our goals and accordingly devised plans for inspecting pharmaceutical companies, medical shops, medical device manufacturing companies, and blood banks across the state,” said Kamalasan Reddy.

Emerging pharmaceutical hub

This story is from the BioSpectrum India Oct 2024 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the BioSpectrum India Oct 2024 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIO SPECTRUMView All
Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities
Bio Spectrum

Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities

Agilent Technologies Inc. has announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions.

time-read
1 min  |
BioSpectrum India Dec 2024
Univercells Technologies launches miniaturised scale-X Nexo Bioreactor
Bio Spectrum

Univercells Technologies launches miniaturised scale-X Nexo Bioreactor

Univercells Technologies has announced the launch of its latest innovation, the scale-X nexo bioreactor.

time-read
1 min  |
BioSpectrum India Dec 2024
Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics
Bio Spectrum

Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics

Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.

time-read
1 min  |
BioSpectrum India Dec 2024
VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors
Bio Spectrum

VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors

Chennai-based VFL Sciences has announced the launch of GreatFlo Parallel, a range of seamlessly parallel Bioreactors and Fermentors at the IKMC 2024 event organised by IKP Knowledge Park at Hyderabad recently, by Dr Jitendra Kumar, Managing Director, BIRAC.

time-read
1 min  |
BioSpectrum India Dec 2024
Avantor opens new innovation centre for solving life science's biggest challenges
Bio Spectrum

Avantor opens new innovation centre for solving life science's biggest challenges

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced the opening of its new flagship Bridgewater Innovation Centre.

time-read
1 min  |
BioSpectrum India Dec 2024
Waters unveils new software to deliver lab-centric business intelligence
Bio Spectrum

Waters unveils new software to deliver lab-centric business intelligence

Waters Corporation has announced the launch of waters connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organise, analyse, and drive productivity from laboratory information.

time-read
1 min  |
BioSpectrum India Dec 2024
INST develops unique drug delivery method to improve treatment of brain TB
Bio Spectrum

INST develops unique drug delivery method to improve treatment of brain TB

Researchers at the Institute of Nano Science and Technology (INST), Mohali, have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines.

time-read
1 min  |
BioSpectrum India Dec 2024
New way to create hydrogels from viral protein fragments for improving drug delivery
Bio Spectrum

New way to create hydrogels from viral protein fragments for improving drug delivery

Researchers from Bose Institute, an autonomous institute of the Department of Science and Technology (DST), in Kolkata, have discovered a new way to create hydrogels using tiny protein fragments of just five amino acids from the SARS-CoV-1 virus, that could help improve targeted drug delivery & reduce side effects.

time-read
1 min  |
BioSpectrum India Dec 2024
Lupin appoints Claus Jepsen as President, Global Specialty
Bio Spectrum

Lupin appoints Claus Jepsen as President, Global Specialty

Global pharma major Lupin has announced the appointment of Claus Jepsen as President, Global Specialty.

time-read
1 min  |
BioSpectrum India Dec 2024
Shyamakant Giri to join as CEO of Gland Pharma
Bio Spectrum

Shyamakant Giri to join as CEO of Gland Pharma

Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company.

time-read
1 min  |
BioSpectrum India Dec 2024